Single-Atom Gadolinium Nano-Contrast Agents with High Stability for Tumor T1 Magnetic Resonance Imaging

ACS Nano. 2023 May 9;17(9):8053-8063. doi: 10.1021/acsnano.2c09664. Epub 2023 Apr 24.

Abstract

Gadolinium chelates for tumor magnetic resonance imaging (MRI) face challenges such as inadequate sensitivity, lack of selectivity, and risk of Gd leakage. This study presents a single-atom Gd nano-contrast agent (Gd-SA) that enhances tumor MRI. Isolated Gd atoms coordinated by six N atoms and two O atoms are atomically dispersed on a hollow carbon nanosphere, allowing the maximum utilization of Gd atoms with reduced risk of toxic Gd ion leakage. Owning to the large surface area and fast exchange of relaxed water molecules, Gd-SA shows excellent T1-weighted magnetic resonance enhancement with a r1 value of 11.05 mM-1 s-1 at 7 T, which is 3.6 times that of the commercial gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA). In vivo MRI results show that the Gd-SA has a higher spatial resolution and a wider imaging time window for tumors than Gd-DTPA, with low hematological, hepatic, and nephric toxicities. These advantages demonstrate the great potential of single-atom Gd-based nanomaterials as safe, efficient, and long-term MRI contrast agents for cancer diagnosis.

Keywords: MRI; Single-atom nanomaterial; contrast agents; gadolinium; tumor imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Contrast Media
  • Gadolinium
  • Gadolinium DTPA*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Neoplasms* / diagnostic imaging

Substances

  • Gadolinium DTPA
  • Gadolinium
  • Contrast Media